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Summarv 
The pharmacological profile of the competitive muscarinic antagonist S-(-)-o- 
(hydroxymethyl)benzeneacetic a id I-methyl-4-piperidinyl ester (S-(-)-ET 126) 
was evaluated on Ml (rabbit vas deferens; pA2=8.99), M2 (rat left atrium; 
pA2=8.21) and M3 (rat ileum; pA2=6.84) muscarinic receptors in comparison 
with pirenzepine. The drug shows a subtype selectivity (Ml/Mz=8; 
Mt/M3=178; M2/M3=22) that proposes it as a useful pharmacological tool for 
receptor studies. S-(-)-ET 126, like pirenzepine, prevents the antinociception 
induced by Mt agonists (McN-A-343 and AF-102B). Unlike pirenzepine and 
spirotramine, the compound is able to cross the blood brain barrier which makes 
it useful for in vivo investigations. 
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Radioligand binding and functional studies with selective agonists and antagonists have 
demonstrated that there are at least three pharmacologically distinct muscarinic receptor 
subtypes (MI-MT) (1, 2). Antagonists used in this subclassification include pirenzepine (Ml), 
AF-DX 116, methoctramine, himbacine (M2) and HHSiD, p-F-HHSiD, sila-hexocyclium and 
4-DAMP (M3) (for reviews see 2, 3). Molecular cloning tecniques have recently revealed in 
various animal mammalian species the existence of five distinct molecular muscarinic receptor 
proteins (ml-rns) (4, 5,6,7, 8). The antagonist binding properties of the cloned receptors sho- 
wed a close correlation between the nit, ma and mg gene products and the pharmacologically 
defined Ml, M2 and M3 muscarinic receptor subtypes (6, 9, IO). 
It has long been known that the activation of the cholinergic system induces antinociception in 
laboratory animals (11, 12, 13, 14, 15, 16, 17). Bartolini et al. (18) have demonstrated that mu- 
scarinic analgesia in mice and rats is mediated by postsynaptic Mt receptors. These authors 
reported that Mt selective agonists McN-A-343 and AF-102B were able to produce a significant 
enhancement of the pain threshold while the M2 selective agonist arecaidine propargil ester 
(APE) was not. Moreover, Bartolini et al. (18) have demonstrated that the Mt antagonists 
dicyclomine and pirenzepine, contrary to the M2 antagonist AF-DX 116, antagonized 
antinociception induced by both unselective (oxotremorine) and Ml selective (McN-A-343, AF- 
102B) muscarinic agonists. 
Correspondence should be addressed to: Dr. Carla Ghelardini, Department of Pharmacology, 
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In order to investigate the properties of each muscarinic receptor subtype, selective ligands are 
necessary. To date, compounds that are able to consistently discriminate between Mt and M3 
muscarinic receptor subtypes are not available. Therefore we thought it important to further 
evaluate the pharmacological profile of the compound (S-(-)-or-(hydroxymethyl)benzene- acetic 
acid 1-methyl-4-piperidinyl ester) currently designed as S-(-)-ET 126 which is structurally 
related to atropine (Fig. 1) and has already been described (19). First, in vitro functional studies 
were carried out to determine S-(-)-ET 126 affinity towards rabbit vas deferens Mt receptors 
(20), rat atria1 M2 and rat ilenl M3 (21) receptors. Second, in vivo antinociception experiments 
were performed to determine the ability of S-(-)-ET 126 to antagonize antinociception induced 
by Mr agonists. 
FIG. 1 
Steric structure of S-(-)-ET 126 
Methods 
In vitro functional studizs 
Rabbit isolated vas deferens: Experiments on isolated rabbits vas deferens were performed ac- 
cording to Eltze et al. (21). 
Rat isolated left atria and ileum : Isolated left atria and ileum fragments were prepared according 
to Paton and Zar (22). Bath tluid temperriture was maintained at 32’C (atria) and 37 “C (ileum), 
respectively. Atria were electrically stimulated (2 Hz, 3 ms, 10 V) by means of two platinum 
electrodes. Carbuchol negative inotropic effects on isometric atria contractions and isotonic i- 
leum contractions induced by ACh were recorded before and 1 h after perfusion with 
antagonists. 
Determination oj~aruagonist ajj7rtitie.s : After a stabilization time of 30-60 min, agonist concen- 
tration-response curves were plotted before and after equilibration with antagonists. In separate 
control experiments no significant changes in tissue sensitivity to the agonist were observed 
over the period required for the determination of two concetration-response curves. Three 
different concentrations of each antagonist were used (log cont. interval 0.5; n= 4-6 for each 
cont.). The antagonists were allowed to equilibrate for 60 min. No more than two 
concentrations of antagonist were tested in the same preparation. Agonist EC,, values in the 
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FIG. 2 
Antagonism by S-(-)-ET 126 of muscarinic receptors mediating inhibi- 
tion of rabbit vas deferens. Concentration-response curves for McN-A- 
343 in the absence (0) or in the presence of increasing concentrations 
(0 1~10-~;~2xlO-~; 15x10eXM) of S-(-)-ET 126. 
Each point represents the mean f s.e.m. of at least 4 experiments. 
Insert: Schild analysis of antagonism of McN-A-343-induced contrac- 
tions. 
absence and in the presence of antagonists were determined graphically for the calculation of a 
dose ratios. The slope of Arunlakshana-Schild plots (23) were determinated by linear regres- 
sion, according to the least-squares method. pA2 values were estimated by fitting the best 
straight line to the data with a slope of unity as required by the theory (24). 
In vivo antinocicention exoeriments 
Hot plate test : Male Swiss albino mice (23-308) were placed inside a stainless steel container, 
thermostatically set 52.5 z!z 0.1 ‘C in a precision water-bath from CW Mechanical Workshop, 
Siena, Italy. Reaction times (set), were measured with a stopwatch before and at 15, 30, 45 
and 60 min after treatment. The endpoint used was the licking of the fore or hind paws. Those 
mice scoring below 12 and over 18 s in the pretest were rejected. An arbitrary cut-off time of 45 
s was adopted. 
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FIG. 3 
Antagonistic effect of S-(-)-ET 126 on muscarinic receptors mediating 
inhibition of rat left atrium. Concentration-response curves for carba- 
chol in the absence (0) or in the presence of increasing concentrations 
( 0 3x10s; 0 1~10-~; W 1~10.~ M) of S-(-)-ET 126. 
Each point represents the mean + s.e.m. of at least 4 experiments. 
Insert: Schild analysis of antagonism of carbachol-induced contractions. 
Data are presented as means k s.e.m. of n experiments. Differences between mean values we- 
re tested for statistical significance by Student’s I test; the level of significance chosen was P< 
0.05. 
The following drugs were used: S-(-)-ET 126 (S-(-)-or-(hydroxymethyl)benzene-acetic a id l- 
methyl-4-piperidinyl ester; prepared in the Department of Pharmaceutical Sciences of Florence, 
Italy as previously described by Gualtieri et al. (19); the compound has an optical purity greater 
than 97%); acetylcholine chloride (Merck); pirenzepine dihydrochloride and McN-A-343 4-(N- 
[3-chlorophenyl]-carbnmoyloxy)-2-butynyl-trin~ethylammoniun~ chloride (R.B.I.); carbamyl- 
choline chloride, atropine sulphate and yohimbine hydrochloride (Sigma); AF-102B (Inst. for 
Neurobiol. Res., Bruxelles, Belgium). Other chemicals were of the highest quality commer- 
cially available. All the drugs were dissolved in the nutritive solutions immediately before use. 
The concentrations given in the text are expressed as salts. Drug concentrations were prepared 
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FIG. 4 
Antagonistic effect of S-(-)-ET 126 on muscarinic receptors mediating 
contraction of rat ileum. Concentration-response curves for acetylcho- 
line in the absence (0) or in the presence of increasing concentrations 
(0 1x10-$ El 5x10-s; n 1~10.~ M) of S-(-)-ET 126. 
Each point represents the mean + s.e.m. of at least 4 experiments. 
Insert: Schild analysis of antagonism of acetylcholine-induced contrac- 
tions. 
in such a way that the necessary dose could be administered in a volume of 10 ml kg“ by intra- 
peritoneal (i.p.) injection. Intracerebroventricular (i.c.v.) administration was performed under 
ether anaesthesia using isotonic saline as a solvent, according to the method described by Haley 
and McCormick (25). Briefly, during anaesthesia, mice were grasped firmly by the loose skin 
behind the head. A 0.4 mm external diameter, hypodemric needle attached to a 10 c1_1 syringe 
was inserted perpendicularly through the skull, no more than 2 mm into the brain of the mouse, 
where 5 ~1 were then administered. The injection site was 1 mm from the midline along a line 
drawn through to the anterior base of the ears. To ascertain the exact point into which the drugs 
were administered, some mice were injected i.c.v. with 5 yl of diluited 1:lO Indian ink and 
their brains examined macroscopically after sectioning. 
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Results I 
In vitro functional studies: S-(-)-ET 126 concentration-dependently blocked the McN-A-343- 
induced inhibition of twitch contractions of rabbit vas deferens (Fig. 2). S-(-)-ET 126 
antagonized the negative inotropic carbachol-induced effect in rat left atrium (Fig. 3) and the 
contractile responses to acetylcholine in rat ileum (Fig. 4). Increasing concentrations of S-(-)- 
ET 126 produced parallel shifts of the agonist concentration-response curves progressively to 
the right. No appreciable change in basal tension or maximum agonist response was observed. 
PA;! values of S-(-)-ET 126 and pirenzepine, used as reference drug, are shown in Table 1. Re- 
gression lines for both compounds were not significantly different from unity (Table 1). The 
selectivity ratios for S-(-)-ET 126 and pirenzepine, obtained as differences between pA2 values, 
are reported in Table 1. 
In viva studies: Regarding the in vivo studies, the antagonism exerted by S-(-)-ET126 (0.01 pg 
per mouse i.c.v.), pirenzepine (0.01 pg per mouse i.c.v.) and atropine (1 pg per mouse i.c.v.) 
of antinociception induced by McN-A-343 (30 pg per mouse i.c.v.) and AF-102B (5 mg kg-l 
i.p.) in the mouse hot-plate test is reported in Fig. 5. Similar results were obtained when S-(-)- 
ET 126 was administered intraperitoneally thus showing that the drug is able to cross the blood 
brain barrier (data not shown). In the same experimental conditions S-(-)-ET 126, pirenzepine 
and atropine did not modify the pain threshold when given alone (Fig. 5). 
Discussion 
The receptor selectivity profile of the tropic acid ester S-(-)-ET I26 was evaluated by using in 
vitro functional studies in comparison with the reference drug pirenzepine. These data were 
supported by in vivo behavioral experiments. 
As shown by functional studies, S-(-)-ET 126 interacts with the muscarinic receptor as a 
competitive antagonist. In fact, agonist concentration-response curves were parallely displaced 
to the right without depression of maximum responses. Moreover, the slopes of the Schild 
regression lines were not significantly different from unity. These studies revealed that S-(-)-ET 
126 has an affinity for Mi receptors in rabbit vas deferens (pA2 = 8.99) and for M2 receptors in 
rat left atrium (pA2 = 8.21) that are respectively about IO- and lOO-fold higher than those 
obtained for pirenzepine (PA;! = 7.89 for Ml; pA2 = 6.47 for M2). On the other hand, S-(-)-ET 
126 (pA2 = 6.84) and pirenzepine (pKa = 6.61) show similar pA2 values for the M3 receptor 
subtype. Regarding the capability of discriminating among the different muscarinic receptor 
subtypes, S-(-)-ET 126 is able to better discriminate between Ml/M3 and between M2/Ms re- 
ceptors than pirenzepine. S-(-)-ET 126 has, in fact, a selectivity ratio of 178 with respect to 
Ml/M3 and of 22 with respect to M2/Ms. In our hands pirenzepine exhibits selectivity ratios of 
21 for Ml/M3 and 1 for M2/M3 and these findings are in good accord with the selectivity 
reported in the literature (26). By contrast, S-(-)-ET 126 shows about a 4-time lower ability to 
discriminate between Mi and M2 receptors than pirenzepine (selectivity ratio MI/MT= 29 for 
pirenzepine and 8 for S-(-)-ET 126). 
In order to confirm the Mi antagonistic properties of S-(-)-ET 126 by using in vivo behavioral 
studies, the ability of S-(-)-ET 126 to prevent muscarinic analgesia was evaluated. It has been 
in fact reported that the analgesic effect subsequent o the activation of the cholinergic system is 
mediated by the Mi receptor subtype (see introduction). S-(-)-ET 126, like pirenzepine and 
atropine, is able to prevent analgesia induced by Mi agonists such as McN-A-343 (27) and AF- 
102B (28) in the mouse hot-ptate test. Since the doses of S-(-)-ET 126 and pirenzepine able to 
antagonise muscarinic antinociception are 100 times lower than the minimal dose of atropine 
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i 
saline McN-A-343 
30 pg per mouse 
-7 AF-IO2B 5 mg kg 
saline 5 pl per mouse i.c.v. 
S-(-)-ET 126 0.01 pg per mouse i.c.v. 
IZI pirenzepine 0.0 1 yg per mouse i.c.v. 
cl $$fi atropine 1 pg per mouse i.c.v. 
FIG. 5 
Antagonism by S-(-)-ET-126, pirenzepine and atropine of McN-A-343 and 
AF-102B induced antinociception. The antagonistic effect was measured 
respectively 15 and 30 min after administration of analgesic drugs corre- 
sponding to the time of their maximum antinociceptive effect. Vertical li- 
nes represent s.e.m. The number of mice ranged between 8 and 20. 
**PC 0.01 in comparison with saline treated animals. 
necessary to prevent muscarinic antinociception (18) (Fig. S), it is evident that the antagonism 
obtained at such low doses is selective for Mt receptors. 
In conclusion, we have shown that S-(-)-ET 126 is a potent and selective Mr antagonist. This 
compound displays not only a higher affinity for muscarinic receptors but also a higher 
discriminative activity than pirenzepine and the recently reported Mt antagonist spirotramine 
(29). Unlike pirenzepine and spirotramine, S-(-)-ET 126 is able to cross the blood brain barrier. 
The muscarinic antagonists available to date are not as capable of discriminating between 
Vol. 58, No. 12, 1996 S-(-)-ET 133 M, Antagonist !?!?9 
Ml/M3 and quite often have difficulty in reaching the central nervous system. S-(-)-ET 126 is 
thus also active as an Mr antagonist when injected in mice and represents useful tool for 
investigation into the physiological role of the Mr muscarinic receptor subtype. 
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